Phillips 66 heads into the final days of May with a fresh upgrade, a rolling back of the bearish positioning that defined the stock a week ago, and a price that has pulled back sharply enough to put the analyst consensus firmly above the market.
The standout development is today's move from Mizuho. Analyst Nitin Kumar upgraded PSX to Outperform from Neutral and lifted his target to $212 from $170 — a 25% jump in the target that lands it tied with UBS for the highest on the Street. The upgrade matters because it reverses the cautious stance Mizuho held through the stock's recent rally. Goldman Sachs raised its own target to $207 last week, though it kept a Neutral rating. The broader pattern is unambiguous: every major firm has lifted targets since late March, with the consensus mean now at $188. At a close of $173.88, PSX is trading roughly 8% below the average Street target — and the gap is widening as analysts continue to revise up rather than trim.
The options market has stepped back from the aggressive defensive posture flagged in earlier notes. A week ago the put/call ratio was running nearly 2.6 standard deviations above its 20-day average; it has now retreated to 0.92, just 0.7 standard deviations above the mean of 0.90. The 52-week range runs from 0.76 to 1.22, and the current reading sits comfortably in the middle. That is a meaningful shift from the pronounced hedging activity seen around May 18–20, when options traders were pricing in notable downside risk against the rally. The unwind suggests some of that protection has either lapsed or been closed out.
Short positioning has moved in the same direction — but the picture is now clearly one of normalisation, not pressure. Short interest dropped 8% on the week to 1.68% of the free float, unwinding the spike to 1.82% seen on May 18 when shorts added aggressively into the rally. Borrowing costs have fallen sharply too, from around 0.50% earlier in the month to 0.18% — a 37% decline in a week. Availability is effectively uncapped, with far more shares available to borrow than are currently shorted. There is no squeeze dynamic here, and the lending market is giving no signal of concentrated short-side conviction.
The week's price action gives that short retreat some context. PSX fell 4.7% over the past five days to $173.88, giving back part of the 7% monthly gain. The move was broad across the refining complex: closest peer MPC dropped 4.4% on the week, VLO fell 6.6%, and PBF was the worst of the group at -9.2%. The sector-wide selling suggests macro or commodity factors rather than anything PSX-specific. The CFO's decision to sell roughly $5 million in stock on May 8 — at prices just above current levels — is worth noting, though insider selling in this name has been consistent across multiple periods and carries moderate significance scores.
On valuation, the trailing P/E has compressed to 10.3x from 11.4x a month ago, while EV/EBITDA has eased to 7.3x. Those moves reflect the recent price weakness more than any fundamental revision. Factor scores are supportive: dividend quality ranks in the 93rd percentile, EPS momentum over 30 and 90 days ranks in the 82nd and 75th percentile respectively, and the Piotroski F-score has risen from 5 to 7 over the past three months. The ORTEX short score, having briefly ticked up to 31.4 during the mid-May positioning spike, has settled back to 30.3 — well inside neutral territory.
The July 30 earnings date is the next focal point. The two most recent prints produced starkly different reactions — a one-day gain of 8.5% in late April and a one-day loss of 2.2% in mid-May — so the stock is demonstrably sensitive to quarterly surprises. Whether the current price, now sitting below the Morgan Stanley $174 Overweight target, represents a re-entry point or a correction with further to run will depend on the next read on refining margins and midstream performance.
See the live data behind this article on ORTEX.
Open PSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
